Although it pertains to specific populations only (people with established CV disease, at high risk of a CV event or of Aboriginal or Torres Strait Islander origin), it encompasses a surprisingly large proportion of people with type 2 diabetes
Retatrutide is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, improving blood glucose control and promoting weight loss
As described below, ROS may uncouple the eNOS-catalyzed reduction of molecular oxygen from the oxidation of L-arginine, resulting in the paradoxical production of the ROS superoxide anion instead of the reducing NO
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)
Most practitioners recommend 90180 days before assessing efficacy, with optional 30-day breaks between extended cycles to prevent receptor downregulation
When we see improvement there, we know the patients overall health is improving too. 5
